Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors

• Main Authors: Junichi Yoshida (Author), Kenichiro Shiraishi (Author), Tetsuro Tamura (Author), Kazuhiro Otani (Author), Tetsuya Kikuchi (Author), Akiko Mataga (Author), Takako Ueno (Author), Masao Tanaka (Author)
• Format: Book
• Published: BMC, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Casirivimab-imdevimab has been developed to neutralize SARS-CoV-2. The global clinical trials in outpatients documented several adverse effects (AE), which mandate caution in Japan where part of patients return home. To investigate post-infusion clinical events and their risk fac...